CA1083934A - Porte-cupule pour immunoadsorbant - Google Patents

Porte-cupule pour immunoadsorbant

Info

Publication number: CA1083934A
Authority: CA; Canada
Prior art keywords: chamber; chamber holder; antigen; set forth; immunoadsorbent
Prior art date: 1975-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA321,151A

Other languages

English (en)

Inventor

Lavell R. Johnson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Becton Dickinson and Co

Original Assignee

Becton Dickinson and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-04-07

Filing date

1979-02-09

Publication date

1980-08-19

1975-04-07 Priority claimed from US05/565,848 external-priority patent/US4059685A/en

1976-03-24 Priority claimed from CA248,664A external-priority patent/CA1077392A/fr

1979-02-09 Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co

1979-02-09 Priority to CA321,151A priority Critical patent/CA1083934A/fr

1980-08-19 Application granted granted Critical

1980-08-19 Publication of CA1083934A publication Critical patent/CA1083934A/fr

Status Expired legal-status Critical Current

Links

239000000427 antigen Substances 0.000 claims abstract description 93
102000036639 antigens Human genes 0.000 claims abstract description 93
108091007433 antigens Proteins 0.000 claims abstract description 93
239000000758 substrate Substances 0.000 claims abstract description 61
238000000034 method Methods 0.000 claims abstract description 30
238000003556 assay Methods 0.000 claims abstract description 18
239000000203 mixture Substances 0.000 claims abstract description 18
230000018044 dehydration Effects 0.000 claims abstract description 8
238000006297 dehydration reaction Methods 0.000 claims abstract description 8
238000003127 radioimmunoassay Methods 0.000 claims abstract description 6
230000002285 radioactive effect Effects 0.000 claims abstract description 5
229920002307 Dextran Polymers 0.000 claims description 18
229920000642 polymer Polymers 0.000 claims description 17
230000004888 barrier function Effects 0.000 claims description 12
239000011248 coating agent Substances 0.000 claims description 12
238000000576 coating method Methods 0.000 claims description 12
239000011324 bead Substances 0.000 claims description 8
239000002245 particle Substances 0.000 claims description 8
239000011148 porous material Substances 0.000 claims description 7
229920003176 water-insoluble polymer Polymers 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 4
239000012530 fluid Substances 0.000 claims 4
241000272470 Circus Species 0.000 claims 1
239000011521 glass Substances 0.000 description 16
239000000463 material Substances 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000011162 core material Substances 0.000 description 10
239000000047 product Substances 0.000 description 8
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
229920005654 Sephadex Polymers 0.000 description 6
239000012507 Sephadex™ Substances 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000011859 microparticle Substances 0.000 description 5
239000000700 radioactive tracer Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000003610 charcoal Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 4
-1 p-amino-phenoxy-hydroxy-propyl groups Chemical group 0.000 description 4
239000005373 porous glass Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000003463 adsorbent Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
238000012856 packing Methods 0.000 description 3
239000011236 particulate material Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000002861 polymer material Substances 0.000 description 3
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
239000006087 Silane Coupling Agent Substances 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
150000004982 aromatic amines Chemical class 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
150000005676 cyclic carbonates Chemical class 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
150000002540 isothiocyanates Chemical class 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
229910000077 silane Inorganic materials 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
241000208140 Acer Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241000237074 Centris Species 0.000 description 1
229920004943 Delrin® Polymers 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
101100161681 Drosophila melanogaster Acer gene Proteins 0.000 description 1
241000448280 Elates Species 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000218652 Larix Species 0.000 description 1
235000005590 Larix decidua Nutrition 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241001296096 Probles Species 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000193803 Therea Species 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
230000004075 alteration Effects 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
150000004651 carbonic acid esters Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
229940064790 dilantin Drugs 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
229940095886 glucagen Drugs 0.000 description 1
RKGLLHCSSVJTAN-YYICOITRSA-N glucagen Chemical compound Cl.C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 RKGLLHCSSVJTAN-YYICOITRSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000011325 microbead Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011800 void material Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E30/00—Energy generation of nuclear origin
- Y02E30/30—Nuclear fission reactors

Landscapes

Peptides Or Proteins (AREA)

CA321,151A 1975-04-07 1979-02-09 Porte-cupule pour immunoadsorbant Expired CA1083934A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA321,151A CA1083934A (fr)	1975-04-07	1979-02-09	Porte-cupule pour immunoadsorbant

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US05/565,848 US4059685A (en)	1973-03-19	1975-04-07	Immobilized immunoadsorbent
US565,848		1975-04-07
CA248,664A CA1077392A (fr)	1975-04-07	1976-03-24	Particules refractaires recouvertes de polymeres servant d'immunoadsorbants
CA321,151A CA1083934A (fr)	1975-04-07	1979-02-09	Porte-cupule pour immunoadsorbant

Publications (1)

Publication Number	Publication Date
CA1083934A true CA1083934A (fr)	1980-08-19

Family

ID=27164388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA321,151A Expired CA1083934A (fr)	1975-04-07	1979-02-09	Porte-cupule pour immunoadsorbant

Country Status (1)

Country	Link
CA (1)	CA1083934A (fr)

1979
- 1979-02-09 CA CA321,151A patent/CA1083934A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1997-08-19	MKEX	Expiry

Publication	Publication Date	Title
US4180383A (en)	1979-12-25	Chamber holder for immobilized immunoadsorbent
US4059685A (en)	1977-11-22	Immobilized immunoadsorbent
US4166102A (en)	1979-08-28	Immobilized immunoadsorbent
US4695392A (en)	1987-09-22	Magnetic particles for use in separations
US4695393A (en)	1987-09-22	Magnetic particles for use in separations
US4698302A (en)	1987-10-06	Enzymatic reactions using magnetic particles
CA1254028A (fr)	1989-05-16	Particules magnetiques pour procedes de separation
US4672040A (en)	1987-06-09	Magnetic particles for use in separations
US4628037A (en)	1986-12-09	Binding assays employing magnetic particles
CA1304421C (fr)	1992-06-30	Separation d'affinite utilisant des floculants immobilises
US4338094A (en)	1982-07-06	Macroencapsulated immunosorbent assay technique
CA1226215A (fr)	1987-09-01	Dosage immunologique des antigenes
CA1184114A (fr)	1985-03-19	Methode et dispositif d'analyse
US4278651A (en)	1981-07-14	Supported receptor and use thereof in an assay
US4108976A (en)	1978-08-22	Automated direct serum radioimmunoassay
US4280816A (en)	1981-07-28	Macroencapsulated immunosorbent assay technique and element therefor
Hendry et al.	1980	Immobilization of antibodies on nylon for use in enzyme-linked immunoassay
GB2103791A (en)	1983-02-23	Carrier bound immunosorbent
US4108975A (en)	1978-08-22	Radioimmunoassay system
JPH09500446A (ja)	1997-01-14	液状放射性廃棄物からの放射性標識された生物学的分子の除去方法
CA1077392A (fr)	1980-05-13	Particules refractaires recouvertes de polymeres servant d'immunoadsorbants
Akkaya et al.	2012	Concanavalin A immobilized magnetic poly (glycidyl methacrylate) beads for antibody purification
US4223002A (en)	1980-09-16	Isolation of alpha1 -fetoprotein
US4052504A (en)	1977-10-04	Assay for thyroxine binding globulin
CN112505319A (zh)	2021-03-16	一种待检标志物免疫定量检测装置、检测方法及用途